Alzheimer's disease

EIP bags cash to trial ex-Vertex drug in dementia, Huntington's
EIP bags cash to trial ex-Vertex drug in dementia, Huntington's
Fierce Biotech
EIP Pharma
Alzheimer's disease
dementia
Huntington's disease
Flag link:
Clinical-Stage Neurodegenerative Disease Company Files for $86 Million IPO
Clinical-Stage Neurodegenerative Disease Company Files for $86 Million IPO
CP Wire
Cortexyme
IPOs
COR388
Alzheimer's disease
Flag link:
Clinical-Stage Neurodegenerative Disease Company Files for $86 Million IPO
Cortexyme
IPOs
COR388
Alzheimer's disease
Flag link:
Alzheimer's-focused M3 Biotechnology rebrands as Athira Pharma
Alzheimer's-focused M3 Biotechnology rebrands as Athira Pharma
Fierce Biotech
M3 Biotechnology
rebranding
Athira Pharma
Alzheimer's disease
Flag link:
Should Biogen Investors Be Extra Nervous Right Now?
Should Biogen Investors Be Extra Nervous Right Now?
Motley Fool
Biogen
Alzheimer's disease
ICER
investors
Spinraza
Flag link:
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
Motley Fool
Alzheimer's disease
Biogen
aducanumab
Otsuka
Axsome Therapeutics
Amgen
Novartis
Avanir
AVP-786
AXS-05
AMG520
Flag link:
What Are Biopharma Leaders Focused on?
What Are Biopharma Leaders Focused on?
BioSpace
drug pricing
regulatory
innovation
value-based drug pricing
government
Alzheimer's disease
drug manufacturing
Flag link:
Avanir's AVP-786 meets in Phase III for Alzheimer's agitation
Avanir's AVP-786 meets in Phase III for Alzheimer's agitation
BioCentury
Avanir Pharmaceuticals
AVP-786
Alzheimer's disease
Alzheimer's agitation
Flag link:
1 Surprising Reason Alzheimer's Drugs Remain So Elusive
1 Surprising Reason Alzheimer's Drugs Remain So Elusive
Motley Fool
R&D
Alzheimer's disease
drug development
sleep science
Flag link:
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
EP Vantage
Biogen
Alzheimer's disease
Tecfidera
generics
Mylan
Flag link:
Biogen sets new $5 billion stock repurchase program in aftermath of stock plunge
Biogen sets new $5 billion stock repurchase program in aftermath of stock plunge
Marketwatch
Biogen
Alzheimer's disease
stock buyback
Flag link:
Is a severely damaged Biogen looking to shed its ties to a controversial development partner?
Is a severely damaged Biogen looking to shed its ties to a controversial development partner?
Endpoints
Biogen
Eisai
Alzheimer's disease
BAN2401
Flag link:
FDA panel: Neuronix Alzheimer’s therapy fails to prove efficacy
FDA panel: Neuronix Alzheimer’s therapy fails to prove efficacy
Medical Design and Outsourcing
Neuronix
Alzheimer's disease
devices
NeuroAD
transcranial magnetic stimulation
Flag link:
RIP amyloid beta theory? Nope. Biogen partner launches a new PhIII before aducanumab's corpse turned cold
RIP amyloid beta theory? Nope. Biogen partner launches a new PhIII before aducanumab's corpse turned cold
Endpoints
Biogen
Eisai
BAN2401
Alzheimer's disease
clinical trials
Flag link:
How Will The Failure Of Biogen's Alzheimer's Drug, Aducanumab, Impact R&D?
How Will The Failure Of Biogen's Alzheimer's Drug, Aducanumab, Impact R&D?
Forbes
Biogen
R&D
Alzheimer's disease
Flag link:
Where can Biogen turn after mammoth Alzheimer's blow? The M&A table, analysts say
Where can Biogen turn after mammoth Alzheimer's blow? The M&A table, analysts say
Fierce Pharma
Biogen
Alzheimer's disease
aducanumab
M&A
Flag link:
Biogen halts Alzheimer's drug trials in 'transformative' failure for the biotech
Biogen halts Alzheimer's drug trials in 'transformative' failure for the biotech
BioPharma Dive
Biogen
Eisai
Alzheimer's disease
clinical trials
aducanumab
Flag link:
Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival
Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival
Endpoints
Axovant
Alzheimer's disease
Roivant
Vivek Ramaswamy
Urovant
vibegron
urinary incontinence
Flag link:
IBM uses machine learning to detect early Alzheimer’s in blood samples
IBM uses machine learning to detect early Alzheimer’s in blood samples
Fierce Biotech
IBM
machine learning
artificial intelligence
Alzheimer's disease
diagnostics
Flag link:
40 Sites Across The Country To Test New Alzheimer's Drug
40 Sites Across The Country To Test New Alzheimer's Drug
Forbes
clinical trials
Alzheimer's disease
troriluzole
Biohaven
Flag link:

Pages